Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

e-Therapeutics to Raise £40 Million

Published: Tuesday, February 12, 2013
Last Updated: Monday, February 11, 2013
Bookmark and Share
Company to advance lead cancer drug and exploit network pharmacology platform.

e-Therapeutics plc proposes to raise GBP 40 million (approximately GBP 39 million net) through an issue of new ordinary shares to existing and new institutional investors.

The new shares will be priced at 32p, a premium of 4% to the closing mid-market price on the last dealing day before this announcement.

Irrevocable undertakings of support have been received from shareholders representing approximately 86% of the Company’s equity in advance of a general meeting where approval for the issue will be sought.

Following the proposed issue, the Company will have pro-forma net cash and liquid resources of approximately GBP 48 million.

Together with expected receipts from R&D tax credits and interest, these resources are intended to support all of the Company’s currently planned discovery and development activities into 2017, by which time the Directors believe an out-licensing deal could be concluded for the Company’s lead cancer drug, ETS2101.

The principal planned uses of the Company’s enlarged cash resources are:

• to complete phase I trials for ETS2101 and advance the drug seamlessly into and through the next phase of its clinical development, which is expected to include a randomized phase II trial in brain cancer (glioma) and a phase Ib/II trial that will explore the drug’s activity in four to six other cancer indications. e-Therapeutics plans to spend around GBP 25 million on this programme for ETS2101 and expects to complete the studies in time to conclude a licensing deal or deals during 2017 if the data are supportive;

• to continue investment in new drug discovery using the Company’s network pharmacology platform. The Directors are confident that sustained investment in the platform and its application to drug discovery will yield new drug candidates that will drive future value in the business; and

• to advance newly discovered drugs and existing product assets into and through preclinical and clinical development, with the aim of building an increasingly diverse and mature portfolio of drug candidates.

Professor Malcolm Young, Chief Executive Officer of e-Therapeutics, said: “We appreciate the continuing support of existing investors and are also pleased to have attracted significant new investors to the Company. With our financial position secure we are well placed to build further shareholder value based on our innovative platform and product portfolio.”

Dr Daniel Elger, Chief Financial Officer of e-Therapeutics, added: “This fundraising provides us with the resources needed for significant investment in new drug discovery and to take our lead cancer drug ETS2101 through efficacy-focused trials that could lead to a lucrative licensing deal.”

The funds to be raised through the new issue will include a substantial further investment by Invesco Asset Management Limited, whose shareholding will increase from 45.92% to 49.90% after completion.

The Takeover Panel has granted an Accelerated Rule 9 Waiver in respect of the acquisition of new shares by Invesco.

A circular to shareholders, including a notice convening a general meeting, will be dispatched shortly.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

e-Therapeutics’ ETS2101 Enters Phase I Clinical Trial in Brain Cancer
First findings are expected in late 2012.
Wednesday, June 20, 2012
e-Therapeutics’ Preliminary Results for the Year Ended 31 January 2012
Further drugs for infection and depression expected to enter trials in 2012.
Friday, June 15, 2012
Phase I Clinical Trials of Cancer Drug ETS2101 Approved by Regulators
Enrolment of patients into trials will begin shortly.
Thursday, March 29, 2012
e-Therapeutics Outlines Goals for 2012
Company announces presentation at biotech showcase conference.
Thursday, March 01, 2012
Celgene Executive Dr Rajesh Chopra Joins the Board of e-Therapeutics
Dr Chopra has extensive experience of all phases of drug development.
Monday, February 06, 2012
e-Therapeutics Appoints Daniel Elger as Chief Financial Officer
Dr Elger, 41, was previously the VP, Marketing & Communications at cancer drug developer Antisoma plc.
Thursday, July 21, 2011
Scientific News
Drug May Prevent Life-Threatening Muscle Loss in Advanced Cancers
New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health.
Chemical Design Made Easier
Rice University scientists prepare elusive organocatalysts for drug and fine chemical synthesis.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos